IP Library Granted Patent US 12673040
Granted Patent B2
US 12673040 · App. 18/783,734 · Granted Jul 7, 2026

Pharmaceutical composition for treating migraine

Inventors: Prabhu Prabhakara (Udupi, IN); Rajesh Ramesh Patil (Thane, IN); Piyush Gupta (Ghaziabad, IN); Rajeev Singh Raghuvanshi (Gurgaon, IN); Anil N. Namboodiripad (Yardley, PA)
Assignee: Tonix Medicines, Inc.
A61K31/4045A61K9/0019A61K9/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12673040
App. No.
18/783,734
Granted
Jul 7, 2026
Kind
B2
Abstract

The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.

Claims (14)

1 . A delivery system comprising:

a delivery device; and

a pharmaceutical composition formulated for subcutaneous administration comprising an aqueous solution, wherein the aqueous solution comprises 4.2 mg sumatriptan succinate and 4.15 mg to 4.2 mg sodium chloride in a total volume of 0.5 mL, and optionally at least one pharmaceutically acceptable excipient, and

wherein the aqueous solution has osmolality between 275 to 315 mOsm/kg.

2 . The delivery system of claim 1 , wherein the aqueous solution has a pH of about 4.2 to 5.3.

3 . The delivery system of claim 1 , wherein the delivery device comprises a device for autoinjection.

4 . The delivery system of claim 3 , wherein the device for autoinjection comprises a pre-filled syringe disposed within the device for autoinjection.

5 . The delivery system of claim 3 , wherein the device for autoinjection is a single-use, ready-to-use, disposable device for autoinjection.

6 . The delivery system of claim 4 , wherein the pre-filled syringe contains 0.5 mL of the aqueous solution of claim 1 , wherein the aqueous solution comprises 4.2 mg sumatriptan succinate and 4.15 mg to 4.2 mg sodium chloride, and wherein the aqueous solution has osmolality between 275 to 315 mOsm/kg.

7 . The delivery system of claim 4 , wherein the pre-filled syringe comprises a permeable part for sterilization with ethylene oxide.

8 . The delivery system of claim 1 , wherein administration of the pharmaceutical composition to a subject results in a systemic exposure in the subject characterized by one or more of a plasma profile selected from:

(i) C max of about 35 ng/ml to about 57 ng/ml;

(ii) AUC 0-2 of about 30 ng·hr/mL to about 50 ng·hr/mL; and

(iii) AUC 0-inf of about 43 ng·hr/mL to about 70 ng·hr/mL.